PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Actinium Pharmaceuticals, Inc. (ATNM)
1.780.01 (-0.56%)
1.75 - 1.81
1.03 - 2.41
122.5K / 296.7K (Avg.)
-1.36 | -1.31
Identifies how quickly the company is scaling its balance sheet (via acquisitions, expansions, or debt). Strong growth, accompanied by sound fundamentals, can support long-term intrinsic value—while disproportionate debt expansion or bloated intangible assets can signal elevated risk.
-7.65%
Both companies show declining cash positions (-7.65% vs CRVO's -27.47%). Seth Klarman would examine if this reflects broader market conditions or operational challenges.
No Data
No Data available this quarter, please select a different quarter.
-7.65%
Below half of CRVO's -27.47%. Michael Burry might suspect a liquidity shortfall if there's no alternative capital plan.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
0.05%
Higher Other Current Assets Growth compared to CRVO's zero value, indicating worse performance.
-5.46%
Below half of CRVO's -22.95%. Michael Burry could suspect a liquidity squeeze. Verify operational performance.
13.35%
Below half CRVO's -7.63%. Michael Burry sees potential underinvestment risk unless there's a valid reason (asset-light model).
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
0.05%
Less than half of CRVO's 13.28%. David Dodd sees fewer expansions in non-core assets. Possibly a simpler focus.
2.60%
Below half of CRVO's -22.76%. Michael Burry might suspect stagnation or lack of resources for expansions.
No Data
No Data available this quarter, please select a different quarter.
-5.18%
Below half of CRVO's -22.86%. Michael Burry sees a potential red flag for stagnation or capital shortage.
41.04%
Similar yoy growth to CRVO's 54.05%. Walter Schloss sees parallel payables strategy. Check top-line correlation.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
47.09%
Less than half of CRVO's -14.98%. David Dodd sees a more disciplined short-term liability approach.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
47.41%
Less than half of CRVO's -3.59%. David Dodd sees far fewer liability expansions relative to competitor.
4.74%
Less than half of CRVO's -93.32%. David Dodd sees fewer share issuances vs. competitor.
-3.50%
Below half CRVO's -7.49%. Michael Burry suspects major net losses or high dividends vs. competitor.
-4.99%
Higher AOCI Growth compared to CRVO's zero value, indicating worse performance.
No Data
No Data available this quarter, please select a different quarter.
-23.90%
Similar yoy to CRVO's -25.33%. Walter Schloss sees parallel net worth trends.
-5.18%
Below half CRVO's -22.86%. Michael Burry sees significant shrinkage or inactivity vs. competitor.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
9.42%
Less than half of CRVO's 27.47%. David Dodd sees better deleveraging or stronger cash buildup than competitor.